Legend Biotech Corporation (LEGN)

43.74 -1.40 (-3.10%) At close: 04:00PM EDT

Legend Biotech Corporation

2101 Cottontail Lane
Somerset, NJ 08873
United States
732 317 5050
https://www.legendbiotech.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 1,800

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Ying Huang Ph.D.	CEO & Director	N/A	N/A	1973
Ms. Lori A. Macomber CPA	Chief Financial Officer	N/A	N/A	1971
Mr. Doug Wallace	Vice President of Global Operations	N/A	N/A	N/A
Dr. Guowei Fang Ph.D.	Chief Scientific Officer & Head of Business Development	N/A	N/A	N/A
Joanne Choi	Senior Manager of Investor Relations	N/A	N/A	N/A
Mr. James Pepin J.D.	General Counsel	N/A	N/A	N/A
Deborah Wong	Executive Director of Strategic Marketing & Corporate Communications	N/A	N/A	N/A
Ms. Elaine Qian	VP & Global Head of Human Resources	N/A	N/A	N/A
Dr. Yuhong Qiu Ph.D.	Senior Vice President of Global Regulatory Affairs	N/A	N/A	N/A
Mr. Steven J. Gavel	Senior Vice President of Commercial Development, US & Europe	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Corporate Governance

Legend Biotech Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.